Ophthalmic surgery, lasers & imaging retina最新文献

{"title":"Long-term Outcomes of Faricimab in Previously Treated Neovascular Age-related Macular Degeneration.","authors":"Nitesh Mohan, Matthew J Schulgit, Victor Bellanda, Gabriel Castilho S Barbosa, Andrei Szigiato, Katherine E Talcott, Danny A Mammo, Amy S Babiuch, Peter K Kaiser, Justis P Ehlers, Aleksandra Rachitskaya, Alex Yuan, Sunil K Srivastava, Sumit Sharma","doi":"10.3928/23258160-20260127-02","DOIUrl":"10.3928/23258160-20260127-02","url":null,"abstract":"<p><strong>Background and objective: </strong>The aim of this study was to evaluate long-term outcomes of intravitreal faricimab injections (IFIs) in previously treated neovascular age-related macular degeneration (nAMD).</p><p><strong>Patients and methods: </strong>This retrospective cohort included 204 eyes from 178 patients with nAMD previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Clinical and imaging data were collected at baseline, after three injections, 1 year, 2 years, and final follow-up.</p><p><strong>Results: </strong>Patients were followed for 2.5 ± 0.3 years. Central subfield thickness decreased from 267.6 ± 61.0 µm to 225.8 ± 42.1 µm (<i>P</i> < .001), and treatment intervals extended from 6.5 ± 2.4 to 11.5 ± 8.0 weeks (<i>P</i> < .001). Intraretinal fluid declined from 44.5% to 29.5% (<i>P</i> = .048) and subretinal fluid from 67.5% to 36.8% (<i>P</i> < .001), while vision and pigment epithelial detachment height remained stable. Switching from faricimab to another agent provided no added benefit.</p><p><strong>Conclusion: </strong>Faricimab demonstrated sustained anatomical improvement and treatment durability over 2.5 years, with a subset of patients showing lasting benefit.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"220-226"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world Safety Profile of Avacincaptad Pegol in the Management of Geographic Atrophy.","authors":"Michael Antonietti, Carolina Mercado, Jorge A Fortun, Thomas A Albini, Sander R Dubovy, William E Smiddy, Stephen G Schwartz, Jaclyn L Kovach","doi":"10.3928/23258160-20260305-01","DOIUrl":"10.3928/23258160-20260305-01","url":null,"abstract":"<p><strong>Background and objective: </strong>This study evaluated the safety of intravitreal avacincaptad pegol in treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD).</p><p><strong>Patients and methods: </strong>A retrospective review was conducted of patients treated with avacincaptad pegol at Bascom Palmer Eye Institute from January 2024 to January 2025. Adverse events, side effects, and potential risk factors were recorded.</p><p><strong>Results: </strong>The study analyzed 124 eyes from 83 patients (mean age 81.8 ± 6.4 years; 49.4% male; 91.6% White) who received 409 injections in total. Injection intervals varied: 54 eyes monthly, 55 every other month, and others less frequently. The variability in injection frequency was mostly due to patient difficulty with follow-up. Follow-up ranged 3 to 12 months (median: 5 months). Baseline visual acuity averaged 0.40 (approx. 20/50 Snellen) decreasing slightly to 0.38 (20/53 Snellen)-not statistically significant (<i>P</i> = .628). Most eyes (85.2%) were pseudophakic; 47% of patients had prior neovascular AMD treated with anti-vascular endothelial growth factor (anti-VEGF), and 24.2% were simultaneously being treated for active neovascular AMD in the eye receiving avacincaptad pegol. Sixteen eyes had prior pegcetacoplan treatment. Adverse events were rare. One patient developed culture-negative endophthalmitis 4 days after the third injection, presenting with vision loss to hand motion but improving after intravitreal antibiotics. Side effects occurred in 14 eyes (13.8%) across 10 patients, including intraocular pressure elevation (seven eyes), discomfort (four eyes), visual disturbance (two eyes), and subconjunctival hemorrhage (one eye). Five patients discontinued treatment, and one eye (0.8%) had reactivation of neovascular AMD.</p><p><strong>Conclusion: </strong>Our study highlights the safety profile of avacincaptad pegol for GA, with a low incidence of conversion to neovascular AMD, few adverse events, and manageable side effects.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"251-255"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147530691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Letter to the Editor: Intravitreal Methotrexate for Complex Retinal Detachment.","authors":"Ioanna Ploumi, John B Miller","doi":"10.3928/23258160-20260309-01","DOIUrl":"10.3928/23258160-20260309-01","url":null,"abstract":"","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":"57 4","pages":"269-271"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 Receptor Agonists: Clinical Considerations and Risk Management for Patients Undergoing Ophthalmic Surgery.","authors":"Caroline R Baumal, Stephanie Choi, Konstantin Balonov, Diana V Do","doi":"10.3928/23258160-20260310-01","DOIUrl":"10.3928/23258160-20260310-01","url":null,"abstract":"<p><p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to treat type 2 diabetes and obesity due to their benefits in glycemic control, weight loss, and cardiovascular risk reduction. However, their pharmacologic effect of delayed gastric emptying raises perioperative concerns. Even though ophthalmic procedures are often performed under local or topical anesthesia, there still remains the concern that GLP-1 RA-induced gastroparesis can increase the risk of aspiration. Additionally, adjunctive sedation, conversion to deeper sedation, or general anesthesia is sometimes necessary for ophthalmic surgery. This review outlines the perioperative implications of GLP-1 RA use in ophthalmic surgery, emphasizing the importance of preoperative screening, interdisciplinary coordination, and familiarity with the evolving anesthesia guidelines.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"263-267"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147531748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year Real-world Outcomes With Faricimab in Neovascular Age-related Macular Degeneration.","authors":"David C Tabano, Ferhina S Ali, Durga S Borkar, Theodore Leng, Ayesha Ahmed, Stella Ko, Alayna Myrick, Erin Zwick, Amanda Downey, Giulio Barteselli, Rishi P Singh","doi":"10.3928/23258160-20260302-02","DOIUrl":"10.3928/23258160-20260302-02","url":null,"abstract":"<p><strong>Background and objective: </strong>This study evaluated real-world treatment patterns and 1-year outcomes in patients with neovascular age-related macular degeneration (nAMD) initiating faricimab.</p><p><strong>Patients and methods: </strong>FARETINA-AMD was a retrospective study using data from the IRIS^® Registry for patients diagnosed with nAMD initiating faricimab from February 2022 to March 2023.</p><p><strong>Results: </strong>Included in the study were 2,025 treatment-naive patients (2,184 eyes) and 22,253 patients (26,851 eyes) previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Visual acuity improved by 2.0 ± 15.0 (mean ± SD) letters in treatment-naive eyes (<i>P</i> < .001) and was maintained in previously treated eyes at injection 7. Central subfield thickness (CST) improved by -53.1 ± 64.8 μm in treatment-naive and -28.5 ± 79.7 μm in previously treated eyes (both <i>P</i> < .0001); 78.4% and 66.8%, respectively, had achieved/maintained C<i>ST</i> ≤ 280 μm at injection 7. Dosing frequency was reduced in the second 6 months (mean 2.4-3.2 injections) versus the first 6 months (4.0-4.2) of treatment.</p><p><strong>Conclusion: </strong>Outcomes among patients with nAMD receiving faricimab over 1-year follow-up support the real-world effectiveness and extended durability of treatment.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"242-250"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147531765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Learning to Predict Outcomes and Dosing Frequency With Aflibercept for Macular Edema Following Central Retinal Vein Occlusion.","authors":"Nitish Mehta, Yasha Modi, Fabiana Q Silva, Weiming Du, Hadi Moini, Rishi P Singh","doi":"10.3928/23258160-20251201-02","DOIUrl":"10.3928/23258160-20251201-02","url":null,"abstract":"<p><strong>Background and objective: </strong>This study aimed to develop machine learning algorithms to predict visual and anatomic outcomes and treatment frequency in patients with macular edema following central retinal vein occlusion (MEfCRVO) after intravitreal aflibercept injections (IAI).</p><p><strong>Patients and methods: </strong>Data from patients from the COPERNICUS (<i>n</i> = 107) and GALILEO (<i>n</i> = 91) trials treated with monthly IAI 2 mg for 24 weeks then pro re nata (PRN) through week 52 were used to develop machine learning algorithms.</p><p><strong>Results: </strong>Machine learning algorithms predicted actual values at week 52 with strong correlation for absolute best-corrected visual acuity (BCVA) (<i>r</i> = 0.87), BCVA change from baseline (<i>r</i> = 0.76), ≥ 15-letter gain (area under the curve [AUC] = 0.81), and change in central subfield thickness from baseline (<i>r</i> = 0.76). PRN injection frequency from week 24 to 52 was predicted with high accuracy (AUC = 0.83). Univariate analyses confirmed all predictive factors.</p><p><strong>Conclusion: </strong>Machine learning algorithms predicted outcomes and dosing frequency with high accuracy and may help inform patients' and clinicians' expectations during MEfCRVO management.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"212-218"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146220630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal Methotrexate for Complex Retinal Detachment.","authors":"Marco A Zarbin","doi":"10.3928/23258160-20260126-01","DOIUrl":"https://doi.org/10.3928/23258160-20260126-01","url":null,"abstract":"","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":"57 4","pages":"268-269"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Study of Swept-source Optical Coherence Tomography Angiography Metrics Between Eyes With Adult Onset Vitelliform Dystrophy, Age-related Macular Degeneration, and Healthy Controls.","authors":"Ken Whang, Itika Garg, Iris Deitch Harel, Raviv Katz, Ying Cui, Rebecca Zeng, Margaret Duich, Hannah E Wescott, Thomas Koch, Augustine Bannerman, Grace Baldwin, Archana Nigalye, Ines Lains, Dean Eliott, Nimesh A Patel, Leo A Kim, Demetrios G Vavvas, Joan W Miller, Deeba Hussain, John B Miller","doi":"10.3928/23258160-20260122-02","DOIUrl":"10.3928/23258160-20260122-02","url":null,"abstract":"<p><strong>Background and objective: </strong>The aim of this study was to investigate swept-source OCT angiography (SSOCTA) metrics in adult-onset foveovitelliform dystrophy (AOFVD), intermediate age-related macular degeneration (iAMD), and healthy control eyes.</p><p><strong>Patients and methods: </strong>A cross-sectional study analyzing SS-OCTA foveal avascular zone (FAZ), vessel skeletonized density (VSD), and vessel density (VD) using the ARI network was conducted. A mixed-effects multiple regression model adjusting for age was used for statistical analyses.</p><p><strong>Results: </strong>The cohort included 204 eyes of 125 patients (control, <i>n</i> = 63; iAMD, <i>n</i> = 93; AOFVD, <i>n</i> = 48). Compared to iAMD, AOFVD eyes had significantly reduced VD, VSD, and FAZ circularity on 3 × 3-mm and 6 × 6-mm angiograms, and significantly increased FAZ area and FAZ perimeter on 6 × 6-mm angiograms. There was no difference on 12 × 12-mm angiograms. Compared to controls, AOFVD eyes had significantly reduced FAZ circularity on 3 × 3-mm angiograms.</p><p><strong>Conclusion: </strong>SS-OCTA metrics may help in distinguishing AOFVD from iAMD.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"227-234"},"PeriodicalIF":1.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity of Spectral-Domain Optical Coherence Tomography Angiography for Detection of Retinal Vasculitis.","authors":"Jila Noori, Christian Leal, Kai Ding, Vinay A Shah, Ronald M Kingsley","doi":"10.3928/23258160-20251125-03","DOIUrl":"10.3928/23258160-20251125-03","url":null,"abstract":"<p><strong>Background and objective: </strong>The aim of this study was to evaluate the validity and accuracy of spectral-domain optical coherence tomography angiography (SD-OCTA) in detecting small-vessel retinal vasculitis (RV) at the posterior pole.</p><p><strong>Patients and methods: </strong>In this prospective study, subjects with and without retinal vasculitis on fundus fluorescein angiography (FFA) were identified among the clinic population and imaged with 8 × 8-mm SDOCTA scans centered on the fovea. Retinal vasculitis was detected using a customized method based on increased perivascular retinal thickness on OCTA. Three reviewers evaluated the FFA and composite en-face scans on SD-OCTA. The method's accuracy was assessed by obtaining sensitivity, specificity, negative predictive value, and positive predictive values, together with 95% confidence intervals, where the gold standard was the consensus FFA result.</p><p><strong>Results: </strong>Eighteen eyes without RV and 34 eyes with RV were selected for evaluation. The consensus sensitivity and specificity were 88.2% (<i>P</i> < .0001) and 77.7% (<i>P</i> = .0184), respectively. Several distinct patterns were recognized on OCTA scans based on retina vessel staining, leakage, cystoid macular edema, and ischemia.</p><p><strong>Conclusions: </strong>SD-OCTA is a valid and accurate noninvasive imaging tool that detects small-vessel RV at the posterior pole using customized scans across a wide range of RV etiologies. Future studies combining wide-field images and en-face scans may demonstrate OCTA's usefulness in detecting and monitoring retinal vasculitis.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"160-167"},"PeriodicalIF":1.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146220674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive Bilateral Retinal Pigment Epithelium Atrophy Associated With SBP-101 (Ivospemin) for Pancreatic Cancer: A Case Report.","authors":"Tatsiana Stalmashka, Rosa M Coco Martín","doi":"10.3928/23258160-20251201-01","DOIUrl":"10.3928/23258160-20251201-01","url":null,"abstract":"<p><p>This report presents a rare case of rapidly progressive retinal pigment epithelium (RPE) atrophy in a patient with no prior history of retinal disease, following treatment with the investigational drug SBP-101 (Ivospemin) for pancreatic adenocarcinoma. A 63-year-old male patient presented with complaints of bilateral vision loss, glare, and nyctalopia 2 months after completing a course of chemotherapy. He had been diagnosed with pancreatic adenocarcinoma with hepatic metastases and had participated in a 3-month clinical trial receiving nab-paclitaxel, gemcitabine, and SBP-101. Prior to and during the trial, the patient experienced no visual symptoms. However, at a 2-month follow-up visit, he exhibited RPE alterations, including progressive atrophy affecting the posterior pole. Ocular complications arising from the use of novel chemotherapeutic agents are often overlooked due to their relative infrequency and lack of life-threatening risk. However, careful monitoring of RPE changes in oncology patients is crucial, as the progression of such changes can be unpredictable.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"190-193"},"PeriodicalIF":1.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146053213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}